Fig. 2.

Risk for cardiovascular and kidney outcome in SGLT2i initiators compared to oGLAs in the entire cohort, during the ITT follow up definition. Event rates are presented as number of events per 100 person years of follow up. In black—the unadjusted model; and in grey—the model adjusted to baseline eGFR (as continuous variable) and UACR (as categorical variable). SGLT2i sodium/glucose cotransporter-2 inhibitors; oGLAs other glucose lowering agents; ITT intention to treat; hHF hospitalization for heart failure; ACM all-cause mortality; MI myocardial infract; eGFR estimated glomerular filtration rate; ESKD end stage kidney disease; ER event rate